Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Temozolomide Stories

2008-11-05 15:00:09

TORONTO, Nov. 5 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that it is participating in a GBM (glioblastoma multiforme) Awareness Day as a co-host with Voices Against Brain Cancer. The event will take place on Wednesday, November 12, 2008, at the Four Seasons Hotel in New York City. The panel discussion will begin at 4:15pm ET. Dr. Alan M. Ezrin, President and...

2008-11-03 18:00:20

TORONTO, Nov. 3 /PRNewswire-FirstCall/ -- Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, announced today that Dr. Alan M. Ezrin, President and Chief Executive Officer of the Company, will present a corporate update at Rodman & Renshaw 10th Annual Healthcare Conference, which is being held in New York City from November 10th - 12th at the New York Palace Hotel. Dr. Ezrin will provide an update on the...

2008-11-03 09:00:06

Genentech, Inc. (NYSE:DNA) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) as a therapy for people with previously treated glioblastoma. If accepted by the FDA, the application would be considered for an accelerated approval that allows provisional approval of medicines for cancer or other life-threatening diseases based on preliminary evidence suggesting clinical...

2008-10-24 09:00:07

Gemin X Pharmaceuticals announced today key clinical and preclinical data from studies of two of the Company's novel, targeted cancer therapeutics - obatoclax (GX15-070), an innovative pan-Bcl2 inhibitor; and GMX1777, a novel inhibitor of NAD+ metabolism. These data were presented during the 20th EORTC-NCI-AACR (ENA) Symposium on "Molecular Targets and Cancer Therapeutics," being held in Geneva, Switzerland from October 21 through October 24, 2008. "These multiple poster presentations at...

2008-10-21 12:00:33

VOORHEES, N.J., Oct. 21 /PRNewswire/ -- Glioblastomas account for more than half of all newly diagnosed gliomas in the United States. Healthcare professionals face many challenges in the treatment of glioblastoma, as therapy today remains largely palliative. Recent clinical trials have shown that combining surgery, radiation, and chemotherapy extends survival in a subset of patients, particularly when the chemotherapeutic agent temozolomide is included in the treatment approach. Other...

2008-09-05 03:00:28

Australia-based biotechnology company Cytopia has initiated enrollment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme. The glioblastoma multiforme (GBM) clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite of Phase II studies designed to investigate the anticancer activity...

2008-09-04 21:00:07

MELBOURNE, Australia, Sept. 4 /PRNewswire/ -- Cytopia Limited today announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM). The GBM clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite of Phase II studies designed to investigate the...

2008-08-28 15:00:24

By PALMER, Rebecca ITS name is an unfamiliar mouthful and it is not one of "big cancers". But glioblastoma multiforme is the most common and aggressive primary brain tumour -- and there's no cure. "Despite intense efforts, there's really been little progress made over the last few decades in terms of outcome," says Wellington Hospital neurosurgeon Martin Hunn. "Even with the best treatment we have, which is a combination of surgery, radiotherapy and chemotherapy, the median survival is...

2008-07-24 12:01:22

Bradmer Pharmaceuticals has initiated enrollment in the Phase III Glass-Art trial evaluating Neuradiab, a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme. The Phase III Glass-Art trial is designed to determine the survival benefit derived from, and safety of, adding Neuradiab to the current standard of care therapy, consisting of surgery, radiation and adjuvant chemotherapy (temozolomide), for patients diagnosed with primary...

2008-07-23 09:00:21

TORONTO, July 23 /PRNewswire-FirstCall/ -- July 23, 2008 - Bradmer Pharmaceuticals Inc. (TSX: BMR), a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has initiated enrollment in the Phase III GLASS-ART Trial evaluating Neuradiab(TM), a monoclonal antibody conjugated to Iodine-131, as a front-line therapy for primary glioblastoma multiforme (GBM). The first patient was enrolled at the Preston Robert Tisch Brain Tumor...